Skip to main content

Table 2 Summary of patient characteristics

From: Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis

Patient characteristics Number of studies (n = 299)a, b Percentage of studies
Number of patients 58,412  
Mean (median sample size) 197 (105)c  
Mean % female 53.1d  
Age category
 Adults and elderly (aged ≥18 years) 192 64.21
 Adults only (aged ≥18 to ≤65 years) 56 18.73
 Children only (aged <18 years) 25 8.36
 All ages 10 3.34
 Children and adults (aged ≤65 years) 8 2.68
 Not reported 8 2.68
Cancer typee
 Lung and respiratory 144 48.16
 Breast 110 36.79
 Gynecological 98 32.78
 Hematological 91 30.43
 Unspecified or unknown 87 29.10
 Head and neck 87 29.10
 Gastrointestinal 86 28.76
 Genitourinary 81 27.09
 Sarcoma 47 15.72
 Not reported 43 14.38
 Nervous system 13 4.35
 Skin 11 3.68
 Optic 5 1.67
 Germ cell 5 1.67
 Other 3 1.00
 Adenocarcinoma 2 0.67
 Musculoskeletal 1 0.33
Chemotherapy details
 Cisplatin administeredf 177 59.20
 Cisplatin dose ≥ 50 mg/m2 116 38.80
 Concomitant radiotherapy 12 4.01
 Adjuvant 14 4.68
 Neoadjuvant 4 1.34
Patient background details
 History of motion sickness 19 6.35
 History of CINV 29 9.70
  1. CINV chemotherapy induced nausea and vomiting
  2. aIncludes unpublished data from conference abstracts and trial protocols (Adel et al. 2006, Tabei et al. 2006, Trifilio et al. 2006, Carrec et al. 2007, Kadota et al. 2007, Piyush 2011)
  3. bExcept where indicated otherwise
  4. cOne study did not report sample size (n = 1)
  5. dEighteen studies did not report female population size (n = 18)
  6. eThe majority of studies included patients with different diagnoses
  7. fIncludes the 116 studies with a cisplatin dose ≥ 50 mg/m2